News
HAE
89.25
+1.81%
1.59
Haemonetics (HAE) Shares Cross Above 200 DMA
NASDAQ · 2d ago
Weekly Report: what happened at HAE last week (0415-0419)?
Weekly Report · 4d ago
Analysts See 11% Gains Ahead For The Holdings of IJK
NASDAQ · 04/16 10:36
Weekly Report: what happened at HAE last week (0408-0412)?
Weekly Report · 04/15 09:02
Haemonetics Price Target Maintained With a $105.00/Share by Barrington Research
Dow Jones · 04/12 14:53
Haemonetics Is Maintained at Outperform by Barrington Research
Dow Jones · 04/12 14:53
Barrington Research Maintains Outperform on Haemonetics, Maintains $105 Price Target
Benzinga · 04/12 14:43
Haemonetics Poised for Growth with Strong Q4 Projections and Strategic Acquisitions
TipRanks · 04/12 13:15
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
NASDAQ · 04/12 13:03
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Haemonetics Corporation (NYSE:HAE) has a price-to-earnings ratio of 34.7x. The company is expected to grow its earnings faster than the market. Its high P/E is typical of a company expected to deliver strong growth in the future. However, the company's high valuation may be a warning sign for investors. Almost half of all companies in the U.S. Have a lower price to earnings ratio than Haemonetics.
Simply Wall St · 04/12 11:25
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024
PR Newswire · 04/10 20:58
Weekly Report: what happened at HAE last week (0401-0405)?
Weekly Report · 04/08 09:02
Haemonetics gets FDA okay for TEG 6s hemostasis cartridge
Healthcare Haemonetics gets FDA okay for TEG 6s hemostasis cartridge. New cartridge extends the viscoeleastic testing capabilities for cardiovascular procedures and liver transplantation. Haemonetic says it has received FDA clearance for its TEG6s Global Hemostasis-HN assay cartridge.
Seeking Alpha · 04/04 21:01
Haemonetics Gets 510 (K) Clearance For TEG 6s Hemostasis - HN Cartridge
NASDAQ · 04/04 11:08
Haemonetics Received 510(k) Clearance From FDA For TEG 6s Hemostasis Analyzer System Global Hemostasis-HN Assay Cartridge
Benzinga · 04/04 10:32
BRIEF-Haemonetics Receives FDA Clearance For New Teg® 6S Global Hemostasis - HN Cartridge
Reuters · 04/04 10:30
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
Haemonetics Corporation has received 510(k) clearance from the U.S. Food and Drug Administration for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. The new cartridge extends Haemonetics' viscoelastic testing capabilities to serve fully heparinized patients in cardiovascular surgeries and liver transplantation. The company is a global medical technology company.
PR Newswire · 04/04 10:30
HAEMONETICS CORPORATION COMPLETES ACQUISITION OF ATTUNE MEDICAL
Reuters · 04/01 12:00
Press Release: Haemonetics Corporation Completes Acquisition of Attune Medical
Haemonetics Corporation Completes Acquisition of Attune Medical. EnsoETM is the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures. Haemonetics expects the company to contribute $30 to $35 million in revenue. The company has completed its previously announced acquisition of privately-held Attune medical.
Dow Jones · 04/01 12:00
More
Webull provides a variety of real-time HAE stock news. You can receive the latest news about Haemonetics Corp Mass through multiple platforms. This information may help you make smarter investment decisions.
About HAE
Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.